HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
fZ4Gtfrzx6YxckEV